Associated Genetic Biomarkers
E1A binding protein p300 (EP300) is a gene that encodes a protein that functions in transcriptional regulation by histone acetylation. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift insertions and deletions, and in-frame insertions and deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
EP300 is altered in 3.60% of all cancers with lung adenocarcinoma, colon adenocarcinoma, bladder urothelial carcinoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in EP300 are EP300 Mutation (4.18%), EP300 Amplification (0.11%), EP300 Loss (0.08%), EP300 D1399N (0.07%), and EP300 M1470Cfs*26 (0.06%) .
EP300 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials that contain EP300 status as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open).
The most frequent alteration to serve as an inclusion eligibility criterion is EP300 Mutation .
Significance of EP300 in Diseases
Follicular Lymphoma +
Urothelial Carcinoma +
Diffuse Large B-Cell Lymphoma +
EP300 is altered in 7.21% of diffuse large B-cell lymphoma patients .
EP300 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EP300 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.